title: O-(beta-hydroxyethyl)-rutosides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications.
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Cesarone
authors.forename: Gianni
authors.initials: G
authors.lastname: Belcaro
authors.forename: Maria Giovanna
authors.initials: MG
authors.lastname: Grossi
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006896:Hydroxyethylrutoside / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008833:Microcirculation / Q000187:drug effects; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D014690:Venous Pressure / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002317:Cardiovascular Agents; D006896:Hydroxyethylrutoside; C005865:troxerutin